Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

FOSUN PHARMA
复星医药

上海復星醫藥（集團）股份有限公司

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02196)

H SHARE RSU FIRST GRANT UNDER THE 2025 H SHARE RSU SCHEME

References are made to the announcement of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the "**Company**") dated 22 August 2025 (the "**Announcement**") in relation to the proposed adoption of the 2025 H Share RSU Scheme and the proposed H Share RSU First Grant and the circular of the Company dated 29 September 2025 (the "**Circular**") in relation to, among other things, the proposed adoption of the 2025 H Share RSU Scheme and the Conditional H Share RSU Grant. Unless otherwise defined, capitalised terms used herein shall have the same meanings as those defined in the Circular.

The 2025 H Share RSU Scheme and the Conditional H Share RSU Grant were approved by the Shareholders at the EGM held on 23 October 2025, and the 2025 H Share RSU Scheme was approved by the shareholders of Fosun International at the general meeting of Fosun International held on the same date. On 4 November 2025, the Board resolved that (i) as 6 proposed grantees had ceased to be employed by the Group and thus ceased to be Eligible Employees, the number of H Share RSU Grantees under the H Share RSU First Grant shall be reduced to 195 from 201, and the number of RSUs under the H Share RSU First Grant shall be reduced to 10,589,500 from 10,696,400; and (ii) the H Share RSU Grant Date of the H Share RSU First Grant shall be 4 November 2025, and the H Share RSU First Grant shall be made on such date.

Therefore, the terms of the H Share RSU First Grant have been updated to reflect the following:

H Share RSU Grant Date : 4 November 2025

Grantees :

(i) Mr. Chen, an executive Director and the chairman of the Board;

(ii) Ms. Guan, an executive Director and the co-chairman of the Board;

(iii) Mr. Wen, an executive Director and the vice chairman of the Board;

(iv) Mr. Wang, an executive Director;

(v) Ms. Yan Jia, the employee Director;

(vi) Mr. Liu, the chief executive officer and president of the Company; and

(vii) 189 other Eligible Employees.

Number of RSUs granted : (i) Mr. Chen: 953,500 RSUs (which represent the right to receive 953,500 Restricted H Shares, representing approximately 0.1763% of the total number of H Shares of the Company in issue (excluding any treasury shares) as at the date of this announcement);

(ii) Ms. Guan: 686,500 RSUs (which represent the right to receive 686,500 Restricted H Shares, representing approximately 0.1269% of the total number of H Shares of the Company in issue (excluding any treasury shares) as at the date of this announcement);

(iii) Mr. Wen: 686,500 RSUs (which represent the right to receive 686,500 Restricted H Shares, representing approximately 0.1269% of the total number of H Shares of the Company in issue (excluding any treasury shares) as at the date of this announcement);

(iv) Mr. Wang: 610,200 RSUs (which represent the right to receive 610,200 Restricted H Shares, representing approximately 0.1128% of the total number of H Shares of the Company in issue (excluding any treasury shares) as at the date of this announcement);

(v) Ms. Yan Jia: 50,900 RSUs (which represent the right to receive 50,900 Restricted H Shares, representing approximately 0.0094% of the total number of H Shares of the Company in issue (excluding any treasury shares) as at the date of this announcement);

(vi) Mr. Liu, 762,800 RSUs (which represent the right to receive 762,800 Restricted H Shares, representing approximately 0.1410% of the total number of H Shares of the Company in issue (excluding any treasury shares) as at the date of this announcement); and

(vii) 189 other Eligible Employees: 6,839,100 RSUs (which represent the right to receive 6,839,100 Restricted H Shares, representing approximately 1.2642% of the total number of H Shares of the Company in issue (excluding any treasury shares) as at the date of this announcement).

Closing price of the H Shares on the date of grant : HK$22.62 per H Share

Financial assistance : As at the date of this announcement, there are no arrangements for the Company or any of its subsidiaries to provide financial assistance to any H Share RSU Grantee to facilitate his or her purchase of H Shares under the H Share RSU First Grant under the H Share RSU Scheme.

Save as disclosed above, the terms of the H Share RSU First Grant as disclosed in the Announcement remain unchanged.

Number of H Shares Available for Future Grant

The total number of H Shares which may be issued and transferred out of treasury in respect of all RSUs to be granted under the H Share RSU Scheme and all options and awards to be granted under any other share scheme(s) of the Company under the H Share Scheme Mandate Limit is 54,097,150 H Shares, representing approximately 10% of the total number of H Shares in issue (excluding any treasury shares) as at the Adoption Date.

Subsequent to the H Share RSU First Grant of 10,589,500 RSUs, the number of H Shares available for future grant under the H Share Scheme Mandate Limit is 43,507,650 H Shares as at the date of the H Share RSU First Grant.

Save as disclosed above, to the best knowledge of the Directors, as at the date of this announcement, none of the grantees under the H Share RSU First Grant is (i) a Director, chief executive or substantial shareholder of the Company or an associate of any of them; (ii) a participant with options and awards granted and to be granted exceeding the 1% individual limit under Rule 17.03D(1) of the Hong Kong Listing Rules; or (iii) a related entity participant or service provider (as defined under the Hong Kong Listing Rules) with options and awards granted and to be granted in any 12-month period exceeding 0.1% of the issued H Shares (excluding treasury shares).

By order of the Board
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*
Chen Yuqing
Chairman

Shanghai, the PRC
4 November 2025

As at the date of this announcement, the executive directors of the Company are Mr. Chen Yuqing, Ms. Guan Xiaohui, Mr. Wen Deyong and Mr. Wang Kexin; the non-executive directors of the Company are Mr. Chen Qiyu and Mr. Pan Donghui; the independent non-executive directors of the Company are Mr. Yu Tze Shan Hailson, Mr. Wang Quandi, Mr. Chen Penghui and Mr. Yang Yucheng; and the employee director of the Company is Ms. Yan Jia.

* *For identification purposes only*